Neogen Chemicals Limited moves to reshape its capital structure

No numerical split has been disclosed. The stated primary use of the proposed Rs 600 Crores QIP is debt reduction and balance-sheet strengthening; the electrolyte/lithium-ion battery-material projects are described as the strategic growth rationale, not as a separately ring-fenced portion of the QIP. Management also indicated that the battery-material capex is being funded through existing debt, promoter equity, Morita JV equity and insurance recoveries rather than a specified direct QIP allocation. ^{[1] [2]}

Leverage impact

The latest quarterly figures are Q1 FY27 consolidated net debt of Rs 1,325.0 Crores, total equity of Rs 816.25 Crores and reported net debt-to-equity of 1.62x. ^{[3] [4] [5]}

† Derived assuming the QIP fully increases equity by Rs 600 Crores, with no transaction costs, subsequent earnings changes or new borrowings. In the debt-repayment case: net debt = Rs 1,325 Crores − Rs 600 Crores = Rs 725 Crores; equity = Rs 816.25 Crores + Rs 600 Crores = Rs 1,416.25 Crores; ratio = 0.51x. In the project-funding case, net debt is assumed unchanged after the cash is spent, while equity rises to Rs 1,416.25 Crores.

Implication: the actual post-QIP ratio cannot be fixed until management specifies the allocation and the proceeds are received and deployed. If “primarily for debt reduction” translates into near-full repayment, leverage could fall from 1.62x to roughly 0.51x; any amount retained for battery-material capex would produce a higher ratio. The QIP therefore appears designed first to deleverage, while preserving capacity to fund the electrolyte and lithium-ion materials ramp through the broader financing plan.

Assuming the entire Rs 600 Crores authorization is issued as equity at the Rs 2,189.73 floor price, the maximum dilution is approximately 9.10% of post-issue equity. The existing share count would rise by about 2.74 million shares, or 27.40 lakh shares.

• Maximum issue size: Rs 600 Crores ^[6]
• QIP floor price: Rs 2,189.73 per share ^[7]
• Implied new shares: Rs 600 Crores / Rs 2,189.73 = approximately 2.74 million
• Existing shares: 27.38 million as of 10 September 2026
• Post-issue shares: approximately 30.12 million
• Existing shareholders’ dilution: 2.74 / 30.12 = 9.10%
• Share-count increase versus the pre-issue base: approximately 10.01%

The 9.10% figure is the relevant ownership dilution; 10.01% is the increase in the number of shares outstanding. This is a maximum-equity-dilution scenario: pricing above the floor, or raising less than Rs 600 Crores, would reduce the number of shares issued. The board authorization also permits instruments other than equity, so the calculation assumes the full amount is raised purely through equity at the floor price ^[6].

Capex alignment

The raise is directionally consistent with funding the company’s expansion program, but its quantitative alignment with FY25 capex cannot be established from the cited disclosure. The board announcement authorizes up to Rs 600 Crores through equity or other eligible securities but does not specify that the entire amount is earmarked for FY25 capex ^[6]. The available news also references a Rs 1,795-crore capex figure in a FY26 results headline, not a clearly stated FY25 capex guidance figure ^[8].

Accordingly, the defensible conclusion is:

• Strategic alignment: likely supports the company’s ongoing expansion and battery-materials investments.
• Funding coverage: not quantifiable against FY25 guidance without the exact FY25 capex amount and stated use-of-proceeds split.
• Capital-structure implication: if fully equity-funded, the raise substitutes part of the expansion funding requirement for additional leverage, at the cost of roughly 9.10% post-issue ownership dilution.

Verdict: The proposed QIP is large relative to Neogen’s historical equity funding, but it is better viewed as a de-leveraging-led growth financing rather than a pure new-project equity raise. The company is using equity to reduce the debt burden created by its capacity build-out, while preserving borrowing headroom for battery-materials and organolithium opportunities.

Capital intensity versus prior expansion funding

The earlier funding model was therefore hybrid: periodic preferential equity supplemented debt. The current battery-materials build-out has been more debt-intensive; management attributed the higher finance cost to increased debt drawdown for Neogen Ionics’ ongoing capex and higher working-capital needs ^[1]. A cited research note also described the approximately Rs 1,800 Crores battery capex as being funded through remaining debt, a Morita contribution of USD 20 million and only Rs 30–40 Crores of Neogen equity ^[9].

What the latest leverage says

The latest reported consolidated balance-sheet metrics are stretched:

• Total debt was Rs 1,329.9 Crores and net debt Rs 1,325.0 Crores, against total equity of Rs 816.25 Crores ^{[10] [3] [4]}.
• Debt/equity was 1.63x and net debt/equity 1.62x ^{[11] [5]}.
• TTM net debt/EBITDA was 8.14x, while TTM interest coverage was only 1.60x ^{[12] [13]}.
• Cash and equivalents were only Rs 4.94 Crores, and the consolidated current ratio was 1.17x ^{[14] [15]}.

At the full Rs 600 Crores size, the QIP equals roughly 45% of current net debt; derived from Rs 600 Crores divided by Rs 1,325.0 Crores ^{[6] [3]}. That is material balance-sheet repair capacity, not a marginal contribution to a new project.

De-leveraging or growth?

Management’s latest commentary gives the clearest signal: it said the company had decided to de-leverage the balance sheet, while also describing the QIP as providing flexibility to optimise debt and create headroom for future growth in battery materials and organolithium ^[1]. The management commentary also indicated that peak debt should settle around Rs 1,000–1,500 Crores after project completion ^[1].

Conclusion: the immediate primary objective appears to be de-leveraging and refinancing the growth already undertaken. The secondary objective is to create capacity for further growth without repeating the recent debt-funded expansion cycle. It is not purely a debt-repayment issue, because the QIP is also tied to long-term capital requirements and future growth opportunities. However, given the 1.63x consolidated debt/equity, 8.14x TTM net debt/EBITDA and 1.60x interest coverage, the balance-sheet need is the stronger explanation for raising equity now.

The precise allocation remains subject to the final issue documents: the board approval was an enabling mandate up to Rs 600 Crores and did not provide an itemised use-of-proceeds schedule ^[2].